New cyclohexylidene 1,2,4,5-tetraoxanes with polar guanidine and urea based
groups were synthesized and evaluated for antimalarial activity against
chloroquine resistant and susceptible Plasmodium falciparum strains.
Derivatives showed moderate nM range antimalarial activities and low
cytotoxicity. N-phenyl-urea derivative 24 exhibited best resistant indices
(RIW2 = 0.44, RITM91C235 = 0.80), and was not toxic against human normal
peripheral blood mononuclear cells (IC50 > 200 ?M). Seven derivatives were
tested in vitro against four human cancer cell lines and they demonstrated
high selectivity toward leukemia K562 cells. One compound, derivative 21 with
a primary amino-group, was the first tetraoxane tested in vivo against
Toxoplasma gondii as another Apicomplexan parasite. Subcutaneous
administration at a dose of 10 mg/kg/day for 8 days allowed survival of 20 %
of infected mice, thus demonstrating the high potential of tetraoxanes for
the treatment of Apicomplexan parasites.
合成了带有极性胍基和脲基的新型环己亚基 1,2,4,5-四氧杂
的抗疟活性进行了评估。
抗氯喹和易感恶性疟原虫菌株的抗疟活性进行了评估。
衍生物显示出中等 nM 范围的抗疟活性和较低的细胞毒性。
细胞毒性。N- 苯基脲衍生物 24 显示出最佳的抗药性指数
(RIW2 = 0.44,RITM91C235 = 0.80),对人体正常外周血单核细胞无毒性。
对人体正常外周血单核细胞无毒性(IC50 > 200 M)。七种衍生物
对四种人类癌细胞系进行了体外测试,结果表明它们对白血病 K
对白血病 K562 细胞具有高选择性。其中一种化合物,即带有
是第一个针对弓形虫进行体内测试的四氧杂环戊烷。
弓形虫(Toxoplasma gondii)的体内试验。皮下注射
以 10 毫克/千克/天的剂量连续给药 8 天,可使 20% 的受感染小鼠存活下来。
受感染小鼠的存活率为 20%。
治疗表皮复合寄生虫的巨大潜力。